Market Research Logo

Arbutus Biopharma Corp (ABUS) - Financial and Strategic SWOT Analysis Review

Arbutus Biopharma Corp (ABUS) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Arbutus Biopharma Corp (Arbutus Biopharma), formerly Tekmira Pharmaceuticals Corporation, is a biopharmaceutical company which focuses on the development and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection. Its pipeline includes HBV candidates such as ARB-1467 for HBsAg expression in patients chronically infected with HBV; ARB-1740 for Hepatitis B virus infection; and Capsid assembly inhibitor (AB-423). The company also has cancer, anti-viral and metabolic programs. Arbutus Biopharma develops product candidates based on its lipid nanoparticle (LNP) delivery technology. It has operational presence in the US and Canada. Arbutus Biopharma is headquartered in British Columbia, Canada.

Arbutus Biopharma Corp Key Recent Developments

May 22,2017: Arbutus Presents HBV Drug Combination Studies at ICAR
May 04,2017: Arbutus Announces Corporate Update and First Quarter 2017 Financial Results
Apr 13,2017: Arbutus Injunction Survives Attempted Appeal by Acuitas
Mar 23,2017: Arbutus Announces Appointment of Daniel Burgess to Board of Directors
Mar 21,2017: Arbutus Announces Year-End 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company 6
Arbutus Biopharma Corp - Key Facts 6
Arbutus Biopharma Corp - Key Employees 7
Arbutus Biopharma Corp - Key Employee Biographies 8
Arbutus Biopharma Corp - Major Products and Services 10
Arbutus Biopharma Corp - History 11
Arbutus Biopharma Corp - Company Statement 14
Arbutus Biopharma Corp - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Section 2 – Company Analysis 18
Arbutus Biopharma Corp - Business Description 18
Arbutus Biopharma Corp - Corporate Strategy 19
Arbutus Biopharma Corp - SWOT Analysis 20
SWOT Analysis - Overview 20
Arbutus Biopharma Corp - Strengths 20
Arbutus Biopharma Corp - Weaknesses 21
Arbutus Biopharma Corp - Opportunities 22
Arbutus Biopharma Corp - Threats 23
Arbutus Biopharma Corp - Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Arbutus Biopharma Corp, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
May 22, 2017: Arbutus Presents HBV Drug Combination Studies at ICAR 34
May 04, 2017: Arbutus Announces Corporate Update and First Quarter 2017 Financial Results 35
Apr 13, 2017: Arbutus Injunction Survives Attempted Appeal by Acuitas 37
Mar 23, 2017: Arbutus Announces Appointment of Daniel Burgess to Board of Directors 38
Mar 21, 2017: Arbutus Announces Year-End 2016 Financial Results 39
Feb 08, 2017: Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology 42
Nov 03, 2016: Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results 43
Aug 08, 2016: Arbutus Announces Issuance of Broad New US Patent for LNP Delivery Technology 45
Aug 04, 2016: Arbutus Provides Corporate Update and Announces Second Quarter 2016 Financial Results 46
Jul 18, 2016: Arbutus to Present Data on New LNP Formulations for Delivery of mRNA at the 2016 Controlled Release Society Conference 49
Section 6 – Appendix 50
Methodology 50
Ratio Definitions 50
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Tables
Arbutus Biopharma Corp, Key Facts 6
Arbutus Biopharma Corp, Key Employees 7
Arbutus Biopharma Corp, Key Employee Biographies 8
Arbutus Biopharma Corp, Major Products and Services 10
Arbutus Biopharma Corp, History 11
Arbutus Biopharma Corp, Subsidiaries 17
Arbutus Biopharma Corp, Key Competitors 24
Arbutus Biopharma Corp, Ratios based on current share price 25
Arbutus Biopharma Corp, Annual Ratios 26
Arbutus Biopharma Corp, Annual Ratios (Cont...1) 27
Arbutus Biopharma Corp, Interim Ratios 29
Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Arbutus Biopharma Corp, Recent Deals Summary 33
Currency Codes 50
Capital Market Ratios 50
Equity Ratios 51
Profitability Ratios 51
Cost Ratios 52
Liquidity Ratios 52
Leverage Ratios 53
Efficiency Ratios 53
List of Figuress
Arbutus Biopharma Corp, Performance Chart (2012 - 2016)
Arbutus Biopharma Corp, Ratio Charts
Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report